Skip to Content
Merck
CN
  • Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed.

Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed.

World journal of gastroenterology (2013-08-22)
Michele Pier Luca Guarino, Silvia Cocca, Annamaria Altomare, Sara Emerenziani, Michele Cicala
ABSTRACT

Gallstone disease represents an important issue in the healthcare system. The principal non-invasive non-surgical medical treatment for cholesterol gallstones is still represented by oral litholysis with bile acids. The first successful and documented dissolution of cholesterol gallstones was achieved in 1972. Since then a large number of investigators all over the world, have been dedicated in biochemical and clinical studies on ursodeoxycholic acid (UDCA), demonstrating its extreme versatility. This editorial is aimed to provide a brief review of recent developments in UDCA use, current indications for its use and, the more recent advances in understanding its effects in terms of an anti-inflammatory drug.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ursodeoxycholic acid, ≥99%
Ursodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard
Ursodeoxycholic acid for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Ursodiol, United States Pharmacopeia (USP) Reference Standard